July 11, 2013
Boehringer Ingelheim (BI) and Eli Lilly and Company have announced the results from the PIII clinical trial of the investigational sodium glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin, which is being codeveloped by the two companies. In the multinational study conducted enrolling...read more